Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy.
暂无分享,去创建一个
R. Mulligan | J. Parkes | R. Thomas | S. Zehntner | C. Schmidt | M. Down | W. Townsend | J. Bell | M. O’Rourke | K. Ellem
[1] G. Thomas,et al. Nuclear localization of RelB is associated with effective antigen-presenting cell function. , 1997, Journal of immunology.
[2] M. de Boer,et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. , 1997, Blood.
[3] N. Favre,et al. Tumor‐infiltrating dendritic cells are defective in their antigen‐presenting function and inducible B7 expression in rats , 1997, International journal of cancer.
[4] G. Halliday,et al. Regression in melanoma: how relevant is it? , 1997 .
[5] G. Halliday,et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. , 1997, The Journal of investigative dermatology.
[6] D. Graves,et al. Antibody to Mac-1 or monocyte chemoattractant protein-1 inhibits monocyte recruitment and promotes tumor growth. , 1997, Journal of immunology.
[7] P. Hansell,et al. Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. , 1997, The Journal of clinical investigation.
[8] E. Gilboa,et al. Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts , 1997, International journal of cancer.
[9] B. Bonnotte,et al. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. , 1997, Advances in experimental medicine and biology.
[10] J. Luck,et al. Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes. , 1996, Anticancer research.
[11] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[12] L. Hakansson,et al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. , 1996, British Journal of Cancer.
[13] P. Hersey,et al. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF , 1996, Melanoma research.
[14] I. Song,et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. , 1996, Cancer research.
[15] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[16] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.
[17] I. Schmidt-Wolf,et al. Cytokines and clinical gene therapy , 1995, European journal of immunology.
[18] M. Amoss,et al. Histopathology of regression in sinclair swine model of melanoma. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[19] R. Rees,et al. Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin‐2 (rhIL‐2) therapy , 1994, British journal of haematology.
[20] Monique Martin,et al. Surface phenotype and functions of tumor‐infiltrating dendritic cells: CD8 expression by a cell subpopulation , 1993, European journal of immunology.
[21] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] G. Murphy,et al. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. , 1993, The Journal of investigative dermatology.
[23] P. Soler,et al. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. , 1993, The Journal of clinical investigation.
[24] N. Martin,et al. Increasing incidence of cutaneous melanoma in Queensland, Australia. , 1992, Journal of the National Cancer Institute.
[25] G. Kaplan,et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing , 1992, The Journal of experimental medicine.
[26] P. Colloby,et al. Is poor prognosis really related to HLA‐DR expression by malignant melanoma cells? , 1992, Histopathology.
[27] Y. Becker,et al. Anticancer role of dendritic cells (DC) in human and experimental cancers--a review. , 1992, Anticancer research.
[28] D. Twardzik,et al. Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in SCID mice. , 1991, In vivo.
[29] G. Halliday,et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. , 1991, The Journal of investigative dermatology.
[30] P. McCue,et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.